Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Epirus grants Livzon Mabpharm license to BOW015 in China and Taiwan

Executive Summary

Five months after reverse merging with Zalicus, Epirus Biopharmaceuticals Inc. (developing biosimilar monoclonal antibodies) has signed on Chinese biotech Livzon Mabpharm Inc. (a subsidiary of Livzon Pharmaceutical Group Inc.) to help develop, manufacture, and commercialize up to five biosimilar antibody drugs.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies